Skip to content
Company Analysis

Rockwell Medical, Inc. RMTI

A comprehensive view of key metrics, scores, and financial health for Rockwell Medical, Inc.

Overview of Rockwell Medical, Inc.

RMTI NCM
Healthcare Drug Manufacturers - Specialty & Generic Framework: Pharma / Mature Biotech Micro Cap
Rockwell Medical, Inc. (RMTI), is a Micro Cap company, in the Drug Manufacturers - Specialty & Generic industry, last closed at $0.62, about 701.6% undervalued vs fair value, -33.5% 1Y return, ranked 903/1122 in sector.
USD 0.62
0.77%
(Delayed)
• Vol 90d: 58.8%
52-Week Range
Market Cap
$26.30M
Enterprise Value
$25.82M
Overall Score
View breakdown
Overall
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Growth
Weak
Profitability
Fair
Health
Fair
Efficiency
Fair
Valuation
Weak
Completeness: 82%
Confidence: 54%
Updated: Mar 8
Top Beats

Quick Facts

Website https://www.rockwellmed.com
HQ Wixom, MI
Employees 244
Fiscal year Dec 31

Next Events

No upcoming events available.

Fair Value Snapshot

Bear Base Bull
$4
$5
$5
Current: $0.62 +702% vs base

Engine Room Money Flow™

Micro Cap

Pharmaceutical / Mature Biotech - Where revenue goes and how value is created

Flow Steps
Total Revenue
$101.5M
21.4%%
Gross Profit
$17.5M
100.9%%
R&D Expense
$19.0K
-98.3%%
Operating Income (EBIT)
$774.0K
112.6%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Pharmaceutical / Mature Biotech

Quality & Reliability Indicators

Cash Conversion
542.9%
Excellent

Strong cash conversion - profit becomes cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
4
Active Leaks
1/4
Improving
1
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Rockwell Medical, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
48
/100
Developing
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
34
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing RMTI's balance between Growth (42.8%), Profitability (26.0%), and Safety (31.2%). Growth 43% Safety 31% Profitability 26%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

79th percentile vs peers
79
Key Signals
Rev Growth YoY 21.4% 77p Revenue CAGR 3Y 17.9% 76p EPS Growth YoY 95.7% 84p
Strengths
  • EPS Growth YoY in top 20% of peers (95.7%, 84th percentile)
  • Growth above peer median with strong metric coverage (75%)
  • Strong liquidity position vs peers
Risks

No significant risks identified for this axis.

Profitability

48th percentile vs peers
48
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

57th percentile vs peers
58
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Rockwell Medical, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$4.97
- - -
+701.6% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000